| |
Newsroom /
Health and Fitness
/
Healthcare
/
Women’s Health Therapeutics, Analysis and Market Forecasts to 2016
Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 
The Global WH Disorder Therapeutics Market is Forecast to Grow Rapidly from 2009 to 2016
Hyderabad,
AP,
India
(prbd.net)
17/08/2010
"Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets"
In 2009, the global women’s health (WH) disorder therapeutics market was estimated to be worth $12.1 billion, after having had a Compound Annual Growth Rate (CAGR) of 2.6% between 2001 and 2009. By 2016, the global WH disorder therapeutics market is estimated to reach $22 billion, indicating a CAGR of 8.8% between 2009 and 2016. Owing to several factors, such as the publication of the Women’s Health Initiative (WHI) study results, a lack of effective therapeutics, the WH disorder therapeutics market grew moderately between 2001 and 2009. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on the menopause therapeutics market.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Womens-Health-Therapeutics-Market-to-2016-High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Drugs-in-Menopause-and-Osteoporosis&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Amgen Inc’s recently launched Prolia, a first-in-class drug for the treatment of postmenopausal osteoporosis, is estimated to generate revenues of $1 billion annually. Merck’s Odanacatib, a cathepsin K inhibitor, has also shown promising results in postmenopausal osteoporosis treatment. The menopause therapeutics market is presently dominated by hormone therapeutics that have highly questionable safety profiles. If approved for treatment and shown to be safer, non-hormones for the treatment of menopause will strongly compete with the currently marketed drugs and will significantly alter the market dynamics, with the potential to drive the menopause market sales up to $7.2 billion by 2016. Pfizer, Merck, NPS Pharmaceuticals, Inc., Æterna Zentaris Inc., BioSante and Depomed Inc. have promising line-ups of first-in-class molecules.
The current WH disorder therapeutics pipeline is promising with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix. In addition, the recent launch of potential blockbuster drugs such as Prolia (Denosumab) for the treatment of postmenopausal osteoporosis will nullify the effect of major drugs such as Fosamax, Boniva and Actonel losing their patents. Thus, the WH disorder therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.
GBI Research, a leading business intelligence provider, has released its latest research “Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets”. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Women’s Health (WH) market. The report analyzes the markets for WH disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Womens-Health-Therapeutics-Market-to-2016-High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Drugs-in-Menopause-and-Osteoporosis&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|